tradmap

FTRE Fortrea Holdings Inc.

$20.00 -5.99%

Data as of close

Healthcare · Services-Medical Laboratories

Fortrea Holdings Inc. (FTRE) is a healthcare company in the Services-Medical Laboratories industry, with a market capitalization of $1.9 billion. Shares last traded at $20.00, 28.6% below their 52-week high. Over the past year the stock is up 99.9%. Net profit margin is -2.6%, above the peer median of -5.4%. Revenue grew 1.0% year over year.

Market Cap
$1.9B
Shares Out
96.5M
EPS (TTM)
-$0.63
P/E (TTM)*
—
P/S Ratio
0.72
P/B Ratio
3.63
Dividend / Share
—
Dividend Yield
—
52-Week High
$28.00
52-Week Low
$8.10
Volume (venue)
122,337
Avg Vol (3m, venue)
105,925.635

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-16.05%
1M
+0.05%
3M
+11.23%
6M
+63.17%
YTD
+15.94%
1Y
+99.85%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
41.05
SMA (50)
$20.31
SMA (200)
$15.71
Price vs SMA50
-1.50%
Price vs SMA200
+27.32%
ATR (14)
$1.73

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$2.7B
Net Income
-$69M
Gross Margin
—
Operating Margin
0.5%
Net Margin
-2.6%
Return on Equity
-12.9%
Return on Assets
-2.5%
Current Ratio
0.97
Debt / Equity
1.94
Revenue Growth (YoY)
+1.0%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 $0.01 2026-10-29
Q2 2026 -$0.14 2026-07-29
Q1 2026 -$0.25 2026-05-05
Q4 2025 (derived) -$0.25 2026-02-26
FY 2025 -$10.81 2026-02-26
Q3 2025 -$0.17 2025-11-05

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Services-Medical Laboratories peers

FTRE vs 14 industry peers (Services-Medical Laboratories), by market cap. Data as of close

P/S vs peers
0.72 / 5.00 med
-86% discount
Net margin vs peers
-2.6% / -5.4% med
above median
1–14 of 14
NTRANatera, Inc.$54.6B—20.18-7.1%-8.49%
LHLabcorp$28.9B28.771.986.9%-1.65%
DGXQuest Diagnostics$27.6B24.442.339.5%-0.44%
GHGuardant Health, Inc.$22.9B—19.38-38.3%-4.45%
CAICaris Life Sciences, Inc.$9.1B86.269.1610.6%-6.50%
GRALGrail, Inc.$6.0B———-6.79%
RDNTRadnet, Inc.$5.8B—2.54-0.9%-0.54%
BLLNBilliontoone, Inc.$5.2B138.0913.109.5%-2.52%
CDNACaredx, Inc.$4.5B35.089.0725.9%-1.68%
VCYTVeracyte, Inc.$3.9B34.457.0220.4%-1.87%
CELCCelcuity Inc.$3.3B———-2.90%
FTREFortrea Holdings Inc.$1.9B—0.72-2.6%-5.99%
PSNLPersonalis, Inc.$1.7B———-0.44%
LMRILumexa Imaging Holdings, Inc.$1.1B———-2.32%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.